Annegret Van der Aa

2.0k citations

41 papers · 1.6k indexed · 1 hit paper · h-index 17

Rheumatology top 1%
- Rheumatoid Arthritis Research and Therapies 12
Hematology top 2%
- Chronic Myeloid Leukemia Treatments 8
- Autoimmune and Inflammatory Disorders Research 5
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 18
- Inflammatory Bowel Disease 11
- Myeloproliferative Neoplasms: Diagnosis and Treatment 5
Immunology top 5%
Oncology top 5%
- Cytokine Signaling Pathways and Interactions 7
Pathology and Forensic Medicine
- Lymphoma Diagnosis and Treatment 5

Co-authors: Chantal Tasset Pille Harrison Frédéric Vanhoutte Florence Namour Maria Greenwald Mykola Stanislavchuk Séverine Vermeire René Westhovens
Cited by: Rheumatology Hematology Genetics
Journals: The Lancet (2 papers)Journal of Clinical Oncology (1 paper)SHILAP Revista de lepidopterología (1 paper)
Partner nations: Belgium United States United Kingdom

In The Last Decade

Annegret Van der Aa

40 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Annegret Van der Aa

Since Specialization

Citations

This map shows the geographic impact of Annegret Van der Aa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annegret Van der Aa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annegret Van der Aa more than expected).

Fields of papers citing papers by Annegret Van der Aa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annegret Van der Aa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annegret Van der Aa. The network helps show where Annegret Van der Aa may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Annegret Van der Aa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Annegret Van der Aa Line = papers co-authored together Annegret Van der Aa links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer The Oncologist ·Melinda A. Pruis,Matthew Krebs,Ruth Plummer,Filip De Vos,Eric Angevin,Hans Prenen,Martin Förster,Glen Clack,Annegret Van der Aa,Marc Tjwa,E. Jansen,Timothy Perera,Martijn P. Lolkema	2023	1
2	Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials Rheumatology and Therapy ·Jacqueline M. Tarrant,René Galien,Wanying Li,Lovely Goyal,Yang Pan,Rachael E. Hawtin,Wangshu Zhang,Annegret Van der Aa,Peter C. Taylor	2020	27
3	Response to Placebo, Measured by Endoscopic Evaluation of Crohn’s Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials Clinical Gastroenterology and Hepatology ·Marjolijn Duijvestein,Jenny Jeyarajah,Leonardo Guizzetti,Guangyong Zou,Claire E. Parker,Tanja van Viegen,Niels Vande Casteele,Reena Khanna,Annegret Van der Aa,William J. Sandborn,Brian G. Feagan,Geert D’Haens,Vipul Jairath	2019	20
4	Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes Arthritis Research & Therapy ·Mark C. Genovese,René Westhovens,Luc Meuleners,Annegret Van der Aa,Pille Harrison,Chantal Tasset,Arthur Kavanaugh	2018	44
5	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial The Lancet ·Philip J. Mease,Laura C. Coates,Philip Helliwell,Mykola Stanislavchuk,Anna Rychlewska-Hańczewska,Anna Dudek,Walid Abi‐Saab,Chantal Tasset,Luc Meuleners,Pille Harrison,R. Besuyen,Annegret Van der Aa,Neelufar Mozaffarian,Joy M. Greer,Rebecca Kunder,Filip Van den Bosch,Dafna D. Gladman	2018	156
6	Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor British Journal of Clinical Pharmacology ·Florence Namour,Liesbeth Fagard,Annegret Van der Aa,Pille Harrison,Yan Xin,Chantal Tasset	2018	21
7	THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks Annals of the Rheumatic Diseases ·Rieke Alten,René Westhovens,Arthur Kavanaugh,Mark C. Genovese,Kevin Winthrop,Maria Greenwald,L Ponce,F J Enriquez,Mykola Stanislavchuk,Minodora Mazur,Alberto Spindler,Regina Cseuz,N. E. Nikulenkova,Maria B Glowacka-Kulesz,István Szombati,Anna Dudek,Luc Meuleners,Chantal Tasset,Pille Harrison,Annegret Van der Aa	2017	3
8	Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) Annals of the Rheumatic Diseases ·Arthur Kavanaugh,Joel M. Kremer,L Ponce,Regina Cseuz,O. V. Reshetko,Mykola Stanislavchuk,Maria Greenwald,Annegret Van der Aa,Frédéric Vanhoutte,Chantal Tasset,Pille Harrison	2016	176
9	A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies Investigational New Drugs ·Geert A. Cirkel,Bojana Milojkovic Kerklaan,Frédéric Vanhoutte,Annegret Van der Aa,Giocondo Lorenzon,Florence Namour,Philippe Pujuguet,Sophie Darquenne,Filip Y.F. de Vos,Tom J. Snijders,Emile E. Voest,Jan H.M. Schellens,Martijn P. Lolkema	2016	53
10	Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions Drug Metabolism Letters ·Florence Namour,Julie Desrivot,Annegret Van der Aa,Pille Harrison,Chantal Tasset,Gerben van’t Klooster	2016	52
11	Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trialbreakdown → The Lancet ·Séverine Vermeire,Stefan Schreiber,Robert Petryka,Tanja Kuehbacher,Xavier Hébuterne,Xavier Roblin,Maria Kłopocka,Adrian Goldiș,Maria Wiśniewska‐Jarosińska,Andrey Baranovsky,Róbert Sike,Kremena Stoyanova,Chantal Tasset,Annegret Van der Aa,Pille Harrison	2016	344
12	Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects British Journal of Clinical Pharmacology ·Florence Namour,René Galien,Tim Van Kaem,Annegret Van der Aa,Frédéric Vanhoutte,Johan Beetens,Gerben van’t Klooster	2016	47
13	Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1) Annals of the Rheumatic Diseases ·René Westhovens,Peter C. Taylor,Rieke Alten,Д. Е. Павлова,Favio Enríquez-Sosa,Minodora Mazur,Maria Greenwald,Annegret Van der Aa,Frédéric Vanhoutte,Chantal Tasset,Pille Harrison	2016	184
14	Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection Clinical Pharmacokinetics ·Florence Namour,Paul M. Diderichsen,Eugène Cox,Béatrice Vayssière,Annegret Van der Aa,Chantal Tasset,Gerben van’t Klooster	2015	113
15	THU0229 Safety and Efficacy of GLPG0634, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis: Results of a 4-Week Phase II a Dose Ranging, Multi-Center Trial Annals of the Rheumatic Diseases ·Frédéric Vanhoutte,Annegret Van der Aa,Luc Meuleners,Gerben van ‘t Klooster	2013	1
16	Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial Annals of the Rheumatic Diseases ·René Westhovens,Filip De Keyser,Д. Г. Рекалов,Е. Л. Насонов,Johan Beetens,Annegret Van der Aa,Piet Wigerinck,Florence Namour,Frédéric Vanhoutte,Patrick Durez	2012	18
17	A twelve-week exploratory phase II trial of GLPG0259 versus placebo in patients with active rheumatoid arthritis and inadequate response to methotrexate Ghent University Academic Bibliography (Ghent University) ·René Westhovens,Filip De Keyser,Дмитро Геннадійович Рекалов,Е. Л. Насонов,Johan Beetens,Annegret Van der Aa,Piet Wigerinck,Florence Namour,Frédéric Vanhoutte,Patrick Durez	2011	1
18	46 A Phase 2a Randomized Placebo-Controlled Double-Blind Multi-Center Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Patients With Moderately Active Ulcerative Colitis Gastroenterology ·Séverine Vermeire,Paul Rutgeerts,Geert D’Haens,Martine De Vos,Brian Bressler,Annegret Van der Aa,Bernard Coulie,Cindy J. Wong,Brian G. Feagan	2010	15
19	T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study Clinical & Experimental Immunology ·Annegret Van der Aa,Niels Hellings,Robert Medaer,G Gelin,Y Palmers,J. Raus,Piet Stinissen	2003	43
20	Identification of overrepresented T cell receptor genes in blood and tissue biopsies by PCR-ELISA Journal of Immunological Methods ·Ann VanderBorght,Annegret Van der Aa,Piet Geusens,Caroline Vandevyver,J. Raus,Piet Stinissen	1999	16

About Annegret Van der Aa

Annegret Van der Aa is a scholar working on Genetics, Hematology and Rheumatology, having authored 41 papers that have together received 1.6k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (18 papers), Rheumatoid Arthritis Research and Therapies (12 papers), Inflammatory Bowel Disease (11 papers), Chronic Myeloid Leukemia Treatments (8 papers), Cytokine Signaling Pathways and Interactions (7 papers), Autoimmune and Inflammatory Disorders Research (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). The work is most often cited by research in Rheumatology (697 citations), Hematology (402 citations) and Genetics (302 citations). Annegret Van der Aa has collaborated with scholars based in Belgium, United States and United Kingdom. Frequent co-authors include Chantal Tasset, Pille Harrison, Frédéric Vanhoutte, Florence Namour, Maria Greenwald, Mykola Stanislavchuk, Séverine Vermeire, René Westhovens, Minodora Mazur and Maria Kłopocka. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact